Open AccessLow Density Lipoprotein Receptor (LDLR) and 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase (HMGCR) Expression are Associated with Platinum-Resistance and Prognosis in Ovarian Carcinoma Patients
Author(s) -
Xueyao Huang,
Wei Xuan,
Sijing Qiao,
Xue Zhang,
Rui Li,
Shunxue Hu,
Hongluan Mao,
Peishu Liu
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s337873
Subject(s) - ldl receptor , ovarian cancer , immunohistochemistry , medicine , lipoprotein , cancer , oncology , cholesterol , reductase , cancer research , endocrinology , biology , enzyme , biochemistry
The efficacy of post-surgery platinum-based chemotherapy, the primary choice for the treatment of ovarian cancer (OC), is greatly reduced by the development of drug-resistance. In this study, we investigated the association of expression low-density lipoprotein receptor (LDLR) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), two cholesterol metabolism-related proteins, in OC tissues and chemoresistance and patient prognosis.